This initiative celebrates the dedication and excellence showcased by visionary leaders and their business ventures.

Explore key insights from ICON's Q4 2024 earnings call, including bookings growth, digital innovation, and strategic partnerships driving 2025 growth targets.

We are thrilled to have Patrick step into this pivotal role,” said Benedikt von Braunmühl, CEO of Rentschler Biopharma. “Patrick’s in-depth understanding of our clients’ needs, coupled with his ...

Microba Life Sciences (ASX:MAP), which has technology for measuring the gut microbiome, has a strategic partnership deal with ...

No. 2 / 2025Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant ...

As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...

However, the shift of strategic direction to wellness has raised uncertainty over Kirin’s long-term growth prospects, where execution plays a key role in integrating the acquired subsidiary and ...

A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...